Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG

Rozanolixizumab Shows Promise​ as Rescue‍ Therapy for Refractory Myasthenia Gravis

A ⁤recent case ‌report highlights the potential of rozanolixizumab as a rescue therapy for patients with⁤ refractory generalized myasthenia gravis (MG), even in ⁤those ‌who are triple seronegative.

Key Findings:

* Effective ⁤Symptom Control: A patient with triple-seronegative MG, unresponsive to other treatments, achieved symptom control with rozanolixizumab.
* Unique IgG Depletion: Rozanolixizumab selectively reduced IgG levels while preserving IgA​ and IgM, unlike plasma exchange (PLEX) wich broadly depletes‍ all immunoglobulins. This suggests preserved⁤ humoral immunity.
* Intercycle Intervals: ‍The patient’s intercycle intervals ranged from 3 ⁤to 7 weeks, ‌differing from⁣ the ​8 weeks observed in the MycarinG trial.
* Immunoglobulin levels: Baseline IgG was 6.7 g/L, minimum precycle IgG was⁢ 3.9 g/L, and the lowest overall IgG was 1.0 g/L.No⁣ severe ⁣adverse effects ⁣were reported.
*⁢ future Research: The authors recommend including seronegative patients in future rozanolixizumab studies to ⁢gather more real-world evidence on its⁢ effectiveness in​ this population.

Reference:

* Takenobu Y, Kikuchi T, ishikawa D, ⁤et al. ‌Rozanolixizumab as‍ rescue therapy in triple seronegative refractory generalized myasthenia gravis. Immunol Med. Published ‌online⁢ November 10, 2025. doi:10.1080/25785826.2025.2582274
* Shaw M. MG ​Symptoms⁣ PRO highlights ‍rozanolixizumab’s impact on⁤ fatigue, ‍weakness.⁢ AJMC. august 22,2025. Accessed November 18, 2025. https://www.ajmc.com/view/mg-symptoms-pro-highlights-rozanolixizumab-s-impact-on-fatigue-weakness